Introduction
At present the techniques for distinguishing normal from malignant tissues and for the classification of neoplastic specimens rest mainly on the microscopic examination of cell morphology after differential staining. Histochemical and immunological criteria are sometimes used to validate the morphological observations. Recent developments in hybridoma technology have provided effective approaches to generate unlimited amounts of well-defined molecular probes for the analysis ofcell surface and circulating antigens. Tumor-specific antigens recognized by monoclonal antibodies have been described for several neoplastic diseases including lymphoma (1), melanoma (2) (3) (4) , and carcinoma of the ovary (5-7), lung (8, 9) , colon (10, 1 1), and breast (12) . These antibodies have been successfully used as confirmatory diagnostic tools for tissue sections and in some cases for in vivo imaging of solid tumors and metastases (2, 10, 12) . Al- ternatively, when the antigenic molecules are shed, immunoas-says have been devised to measure levels in circulating blood and other biological fluids, to be correlated with tumor burden and disease progression. In the case of B cell lymphomas (1) , the idiotype ofthe cell surface immunoglobulin is truly a tumorspecific antigen, as most, though not all (13) , ofthese lymphomas appear to be ofclonal origin (14) . For most solid tumors, careful analysis of antigen specificity has often revealed either crossreactivity with fetal antigens or interindividual variations excluding the use of the antibodies as universal reagents. In other cases, quantitative rather than qualitative differences in antigen expression compared with normal tissues have been found; in these cases, tumor specificity of the antigen becomes an operational definition dependent upon assay configuration and sensitivity.
This report deals with the characterization of a monoclonal antibody to an antigen expressed at the surface ofbasal epidermis and other epithelia. The antibody, which is denoted VM-2, was originally generated against human skin cells derived from psoriatic plaques. VM-2 binds to an antigen expressed by a variety of squamous carcinoma cells both in tissue culture and in biopsies from human lung, cervix, and skin. Cervical carcinoma cells present in exfoliative smears bear the antigen unlike normally differentiated superficial squamous cells and other normal cell types in the same specimen. The antigen recognized by VM-2 is not tumor-specific but tumor-associated in selected sites or preparations. Therefore, we suggest that this antibody may be a useful immunodiagnostic tool in exfoliative cytology such as cervical smears. Isotype Determination of VM-2
Methods
Ouchterlony immunodiffusion. An aliquot of supernatant of VM-2 hybridoma cells was placed into the center well of a 2% agar plate. Monospecific rabbit anti-mouse Ig isotype antibodies (Meloy) were placed in the outer wells and the plate was incubated for 2 h at room temperature and overnight at 4°C. Flexible polyvinylchloride 96-well plates (Costar, Cambridge, MA) were coated with 0.1 mg/ml goat anti-mouse Ig antibodies for 2 h at 37°C and countercoated with a 3% BSA solution for 2 h at 37°C. VM-2 hybridoma supernatant was then incubated at 37°C for 2 h. After being washed with PBS containing 0.1% BSA (PBS-BSA), plates were incubated at 37°C for 2 h with monospecific rabbit anti-mouse Ig isotype antibodies coupled to peroxidase (Zymed). After being washed, plates were incubated with 1 mg/ml orthophenylenediamine and 0.03% H202 in 0.1 M citrate buffer, pH 4.5. Optical density at 630 nm was determined on a Dynatech enzyme-linked immunosorbent assay (ELISA) plate reader (Dynatech Co., Cambridge, MA).
Cellular antibody assay
Adherent cells were grown to subconfluence in 96-well Linbro dishes; cells growing in suspension were allowed to adhere to the 96-well dishes for 30 min at 37°C after precoating of the wells with 50 ul/well of a 0.1% poly L-lysine (Miles Laboratories, Inc., Elkhart, IN) solution in PBS. Cells were then fixed in the wells for 5 min at room temperature with 0.25% glutaraldehyde (Sigma Chemical Co., St. Louis, MO) and Danscher (15) .
Results
We generated several monoclonal antibodies specific for human epidermal cells by fusing SP2/08A2 with the splenocytes of mice that had been immunized with skin cells obtained from psoriatic plaques. The IgG, monoclonal antibody denoted VM-2 binds specifically to the cells in the basal layer of the epidermis and the external root sheet ofhair follicles (Fig. 1) . Occasionally, in some sections, the layer of cells directly above the basal layer was also stained by the antibody though only in focal areas.
After subcloning, stabilization of the VM-2 hybridoma and antibody production from ascites fluid subjected to sodium sulfate precipitation and DEAE-Sephacel fractionation, we studied the reactivity ofthe purified VM-2 to a variety ofcells grown in tissue culture by solid-phase enzyme-linked assays and direct binding assays. The results are summarized in Table I Fig. 2 . Indirect immunofluorescence (Fig. 2 A) , avidin-biotin-immunoperoxidase (Fig. 2 B) , and immunogold-silver (Fig. 2 C) Fig. 3 . A major doublet band at 120,000 mol wt and a band at 100,000 mol wt appear to be specifically immunoprecipitated. Bands of similar molecular weight were obtained from the different positive cell types.
The reactivities of the VM-2 antibody with normal human tissues and biopsies of clinically and pathologically confirmed carcinomas were tested by fluorescence and peroxidase techniques. Results are listed in Table II 
Discussion
During the course of our work on the antigenic characterization of human epidermal cells (16), we noted the discrete specificity of a murine monoclonal antibody, which is denoted VM-2. In many aspects VM-2 presented similar staining characteristics as VM-1, an antibody obtained in the same way and described recently (16) . Whereas many antibodies specifically bound to all epidermal cells, VM-2 appeared to recognize an antigen exclusively expressed on cells from the basal and, in some areas, suprabasal layer of the epidermis and the external root sheet of hair follicles. The aim of the present study was to test the feasibility of using the VM-2 antibody as a recognition tool for malignant squamous cells. Our hypothesis was that the antigen to which VM-2 binds would be a suitable candidate for a tumorassociated antigen. In sites of exfoliative cytology, such as cervical smears, the cellular components normally present originate from the well-differentiated epithelial layers. As these cells do not bear the antigen recognized by the VM-2 antibody, VM-2 reactivity would indicate the presence of abnormal squamous cells, presumably linked to malignant changes. As such, the VM-2 antibody would constitute an attractive immunodiagnostic reagent both available in unlimited amounts and of well-defined specificity due to its monoclonal cellular origin. In order to test the VM-2 antibody, our main focus was cervical exfoliative cytology, since 95% of all cervical carcinomas are of squamous origin (17) . Malignant diseases of the skin, which sometimes require the identification of residual cancer cells after microscopically controlled surgery, for example, would be logical extensions in the evaluation of VM-2.
The cellular antigen for the VM-2 antibody is presumably a differentiation marker rather than tissue-specific since it is expressed by a variety of squamous carcinoma cells both in tissue culture cell lines and in tissue sections, including skin, lung, and cervix. Strikingly, proteins with similar molecular weight (120,000 and 100,000 mol wt) are immunoprecipitated by VM (18) and human pathology (19, 20 Conventional cervical cytology is currently based on Papanicolaou staining (21) (22) (23) (24) . This widely used screening technology, almost unchanged since its inception 30 yr ago, has resulted in a dramatic improvement in life expectancy for cervical cancer patients (25) (26) (27) , thanks to early diagnosis. False positivity and false negativity rates are unfortunately rather high and vary between cancers. We do not yet know to what extent the antigen recognized by the VM-2 antibody is present on dysplastic cervical cells, the premalignant precursors for invasive cervical cancer. Preliminary results on some samples containing cells with either moderate or severe dysplasia seem to indicate that these cells will be recognized by the VM-2 antibody. Studies of many clinically well-documented specimens, tested in parallel by cytology and immunocytology, will be required to determine the antibody's widespread usefulness. These are objectives of our present efforts.
